SHEZF (Shenzhen Hepalink Pharmaceutical Group Co) Research & Development: $31.4 Mil (TTM As of Mar. 2026)


SHEZF Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
64 GF Score
Price $0.47
GF Value $0.57
! 7 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co Research & Development?

Shenzhen Hepalink Pharmaceutical Group Co SHEZF 64 Research & Development is $31.4 Mil as of Mar. 2026. GuruFocus rates SHEZF with a GF Score™ of 64/100 and a GF Value™ of $0.57. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shenzhen Hepalink Pharmaceutical Group Co's Research & Development for the three months ended in Mar. 2026 was $5.3 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $31.4 Mil.

Shenzhen Hepalink Pharmaceutical Group Co  (OTCPK:SHEZF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shenzhen Hepalink Pharmaceutical Group Co Research & Development Related Terms

Shenzhen Hepalink Pharmaceutical Group Co Research & Development Historical Data

* Premium members only.

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co Research & Development Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.71 36.17 25.55 29.12 32.11

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.52 8.74 10.26 7.15 5.29
SHEZF
64GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen Hepalink Pharmaceutical Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $31.4 Mil mean?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Research & Development of $31.4 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors.
Is Shenzhen Hepalink Pharmaceutical Group Co's Research & Development too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Research & Development is $31.4 Mil. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Research & Development compare to ZTS?
Shenzhen Hepalink Pharmaceutical Group Co's Research & Development of $31.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. Shenzhen Hepalink Pharmaceutical Group Co's current Research & Development is $31.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Research & Development of $31.4 Mil. The stock's GF Value™ is $0.57, compared to a current price of $0.47 — trading 17.6% below its estimated fair value. The current Research & Development is $31.4 Mil. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Research & Development is $31.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of $0.47 is trading 17.6% below its estimated GF Value™ of $0.57.

Key valuation signals for SHEZF:

  • Research & Development: $31.4 Mil
  • GF Value™: $0.57 vs. price of $0.47 (17.6% below fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 09989:Hong Kong002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
64GF Score

Get the complete analysis for SHEZF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price
$0.57
GF Value